These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 32747413)

  • 61. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
    Schulte N; Li M; Zhan T; Dreikhausen L; Sollors J; Antoni C; Diehl S; Schoenberg SO; Rahbari N; Reissfelder C; Giordano FA; Ebert MP; Teufel A
    Z Gastroenterol; 2020 Aug; 58(8):773-777. PubMed ID: 32785913
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].
    Li ZC; Ren ZG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):600-603. PubMed ID: 34225439
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Dyhl-Polk A; Mikkelsen MK; Ladekarl M; Nielsen DL
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208788
    [No Abstract]   [Full Text] [Related]  

  • 70. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
    El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
    Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
    Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
    J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Nishida N; Kudo M
    Dig Dis; 2017; 35(6):618-622. PubMed ID: 29040995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.
    Finkelmeier F; Czauderna C; Perkhofer L; Ettrich TJ; Trojan J; Weinmann A; Marquardt JU; Vermehren J; Waidmann O
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):253-259. PubMed ID: 30374657
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.